Q2 2025 Cellectar Biosciences Inc Earnings Call Transcript
Key Points
- Cellectar Biosciences Inc (CLRB) plans to submit a new drug application (NDA) for iopofosine I 131 under an accelerated approval pathway for treating Waldenstrom's macroglobulinemia (WM), aligning with FDA's commitment to expedite treatments for rare diseases.
- The company has received FDA breakthrough therapy designation for iopofosine I 131, enhancing its regulatory strategy and potential for expedited approval.
- Cellectar Biosciences Inc (CLRB) has secured a long-term isotope supply agreement and raised nearly $10 million in recent financings, supporting clinical programs and regulatory milestones.
- The company is advancing its next-generation radiopharmaceutical pipeline, with plans to initiate Phase I trials for CLR 125 and CLR 225, targeting triple-negative breast cancer and solid tumors, respectively.
- Cellectar Biosciences Inc (CLRB) has reduced research and development expenses significantly, reflecting efficient management of clinical study costs and personnel expenses.
- The company's cash position has decreased from $23.3 million at the end of 2024 to $11 million as of June 30, 2025, indicating a need for careful financial management.
- Net loss for the quarter ended June 30, 2025, was $5.4 million, significantly higher than the $0.9 million loss in the same period in 2024, primarily due to noncash impacts of warrant activity.
- The initiation of the CLR 225 Phase I trial is contingent upon obtaining sufficient funding, highlighting financial constraints in advancing the pipeline.
- Cellectar Biosciences Inc (CLRB) requires approximately $40 million to $45 million to complete the confirmatory study for iopofosine I 131, with $20 million to $25 million needed for full enrollment, posing a financial challenge.
- The company's regulatory strategy for iopofosine I 131 in Europe is still pending, with a decision on conditional marketing authorization expected late in the third or early in the fourth quarter of 2025.
Ladies and gentlemen, thank you for standing by, and welcome.
(Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to Anne Marie Fields, Managing Director at Precision AQ. Please go ahead.
Thank you, operator. Good morning, and welcome to Cellectar Biosciences Second Quarter 2025 Financial Results and Business Update Conference Call. Joining us today from Cellectar are Jim Caruso, President and CEO; who will provide an overview of the company's progress before turning the call over to Chad Kolean, CFO, for a financial review of the quarter. Following this, Jarrod Longcor, Chief Operating Officer, will give an update on the company's progress and plans for its promising clinical pipeline of radiopharmaceuticals.
Cellectar issued a press release earlier this morning detailing the content of today's call. A copy can be found on the investor page of Cellectar's corporate website. I want to remind callers that the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
